ACADIA Pharmaceuticals Inc Cash Flow Conversion Efficiency
ACADIA Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, ACADIA Pharmaceuticals Inc (ACAD) has a cash flow conversion efficiency ratio of 0.103x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($134.76 Million) by net assets ($1.31 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ACADIA Pharmaceuticals Inc (2002–2025)
Cash flow conversion efficiency of ACADIA Pharmaceuticals Inc from 2002 to 2025. This chart illustrates how ACADIA Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ACADIA Pharmaceuticals Inc (ACAD) share price today for real-time trading data and today's change.
ACADIA Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
ACADIA Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ACADIA Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACADIA Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see how much is ACADIA Pharmaceuticals Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Choice Properties Real Estate Investment Trust
TO:CHP-UN
|
0.012x |
|
Hanmi Pharm Co Ltd
KO:128940
|
0.031x |
|
BW LPG Ltd
OL:BWLPG
|
0.310x |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
-0.075x |
|
CCOOP Group Co Ltd
SHE:000564
|
-0.008x |
|
SpringWorks Therapeutics Inc
NASDAQ:SWTX
|
-0.165x |
|
China Coal Xinji Energy Co Ltd
SHG:601918
|
0.023x |
|
Kinetik Holdings Inc
NYSE:KNTK
|
0.063x |
Annual Cash Flow Conversion Efficiency for ACADIA Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of ACADIA Pharmaceuticals Inc from 2002 to 2025. Review ACADIA Pharmaceuticals Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.23 Billion | $109.84 Million | 0.089x | -58.42% |
| 2024-12-31 | $732.79 Million | $157.72 Million | 0.215x | +456.38% |
| 2023-12-31 | $431.75 Million | $16.70 Million | 0.039x | +113.58% |
| 2022-12-31 | $400.41 Million | $-114.03 Million | -0.285x | -22.59% |
| 2021-12-31 | $540.89 Million | $-125.66 Million | -0.232x | -6.98% |
| 2020-12-31 | $627.01 Million | $-136.17 Million | -0.217x | -0.46% |
| 2019-12-31 | $699.13 Million | $-151.13 Million | -0.216x | +38.16% |
| 2018-12-31 | $479.08 Million | $-167.47 Million | -0.350x | +46.20% |
| 2017-12-31 | $335.29 Million | $-217.86 Million | -0.650x | -60.09% |
| 2016-12-31 | $518.41 Million | $-210.41 Million | -0.406x | +33.43% |
| 2015-12-31 | $199.76 Million | $-121.80 Million | -0.610x | -184.03% |
| 2014-12-31 | $309.49 Million | $-66.43 Million | -0.215x | -23.06% |
| 2013-12-31 | $182.13 Million | $-31.77 Million | -0.174x | +31.48% |
| 2012-12-31 | $84.98 Million | $-21.63 Million | -0.255x | +70.11% |
| 2011-12-31 | $23.36 Million | $-19.90 Million | -0.852x | -136.24% |
| 2010-12-31 | $29.69 Million | $-10.70 Million | -0.361x | +68.18% |
| 2009-12-31 | $12.11 Million | $-13.73 Million | -1.133x | +7.43% |
| 2008-12-31 | $52.99 Million | $-64.87 Million | -1.224x | -153.92% |
| 2007-12-31 | $113.93 Million | $-54.93 Million | -0.482x | +21.83% |
| 2006-12-31 | $67.16 Million | $-41.42 Million | -0.617x | -19.83% |
| 2005-12-31 | $39.37 Million | $-20.26 Million | -0.515x | +23.70% |
| 2004-12-31 | $30.68 Million | $-20.69 Million | -0.674x | -461.90% |
| 2003-12-31 | $-52.67 Million | $-9.82 Million | 0.186x | -19.17% |
| 2002-12-31 | $-40.09 Million | $-9.24 Million | 0.231x | -- |
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more